Polycythemia Vera - Pipeline Review, H1 2015

Published: Feb, 2015 | Pages: 89 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Polycythemia Vera - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Polycythemia Vera - Pipeline Review, H1 2015', provides an overview of the Polycythemia Vera's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Polycythemia Vera, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polycythemia Vera and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Polycythemia Vera
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Polycythemia Vera and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Polycythemia Vera products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Polycythemia Vera pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Polycythemia Vera
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Polycythemia Vera pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Polycythemia Vera Overview 7
Therapeutics Development 8
Pipeline Products for Polycythemia Vera - Overview 8
Pipeline Products for Polycythemia Vera - Comparative Analysis 9
Polycythemia Vera - Therapeutics under Development by Companies 10
Polycythemia Vera - Therapeutics under Investigation by Universities/Institutes 11
Polycythemia Vera - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Polycythemia Vera - Products under Development by Companies 15
Polycythemia Vera - Products under Investigation by Universities/Institutes 16
Polycythemia Vera - Companies Involved in Therapeutics Development 17
Bristol-Myers Squibb Company 17
Galena Biopharma, Inc. 18
Incyte Corporation 19
Italfarmaco S.p.A. 20
miRagen Therapeutics, Inc. 21
Novartis AG 22
Onconova Therapeutics, Inc. 23
PharmaEssentia Corporation 24
Polycythemia Vera - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
anagrelide hydrochloride CR - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
dasatinib - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
erismodegib - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
givinostat - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
MGN-4893 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
peginterferon alfa-2b - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
rigosertib sodium - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
ruxolitinib phosphate - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Small Molecules to Inhibit JAK for Oncology and Hematological Disorders - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Polycythemia Vera - Recent Pipeline Updates 56
Polycythemia Vera - Dormant Projects 74
Polycythemia Vera - Discontinued Products 75
Polycythemia Vera - Product Development Milestones 76
Featured News & Press Releases 76
Jan 28, 2015: Incyte Announces Publication of Phase III RESPONSE Trial in Patients with Polycythemia Vera in New England Journal of Medicine 76
Jan 28, 2015: Novartis announces study in NEJM showing Jakavi was superior to standard therapy in rare blood cancer polycythemia vera 77
Jan 23, 2015: Incyte Earns $25 Million Milestone as Jakavi (ruxolitinib) Recommended for Approval in Europe for Polycythemia Vera 79
Dec 04, 2014: FDA Approves Jakafi (ruxolitinib) for the Treatment of Patients with Uncontrolled Polycythemia Vera 79
Dec 02, 2014: Multiple Data Presentations at the 2014 American Society of Hematology Annual Meeting Showcase Incyte's Leadership in the Field of Myeloproliferative Neoplasms 81
Nov 18, 2014: Galena Biopharma Completes Enrollment In GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial 83
Aug 05, 2014: FDA Accepts Supplemental New Drug Application for Jakafi (ruxolitinib) and Priority Review Granted 84
Jul 23, 2014: Incyte Announces Top-Line Results from RELIEF Trial of Ruxolitinib in Patients with Polycythemia Vera 84
Jun 03, 2014: Pivotal Phase III Data in Polycythemia Vera Show that Jakafi (ruxolitinib) Achieved Superior Disease Control Compared to Best Available Therapies 86
Mar 07, 2014: Incyte Announces Positive Top-Line Results from Phase III Study of Ruxolitinib in Patients with Polycythemia Vera 87
Appendix 88
Methodology 88
Coverage 88
Secondary Research 88
Primary Research 88
Expert Panel Validation 88
Contact Us 88
Disclaimer 89

List of Tables
Number of Products under Development for Polycythemia Vera, H1 2015 8
Number of Products under Development for Polycythemia Vera - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Number of Products under Investigation by Universities/Institutes, H1 2015 11
Comparative Analysis by Late Stage Development, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 13
Comparative Analysis by Early Stage Development, H1 2015 14
Products under Development by Companies, H1 2015 15
Products under Investigation by Universities/Institutes, H1 2015 16
Polycythemia Vera - Pipeline by Bristol-Myers Squibb Company, H1 2015 17
Polycythemia Vera - Pipeline by Galena Biopharma, Inc., H1 2015 18
Polycythemia Vera - Pipeline by Incyte Corporation, H1 2015 19
Polycythemia Vera - Pipeline by Italfarmaco S.p.A., H1 2015 20
Polycythemia Vera - Pipeline by miRagen Therapeutics, Inc., H1 2015 21
Polycythemia Vera - Pipeline by Novartis AG, H1 2015 22
Polycythemia Vera - Pipeline by Onconova Therapeutics, Inc., H1 2015 23
Polycythemia Vera - Pipeline by PharmaEssentia Corporation, H1 2015 24
Assessment by Monotherapy Products, H1 2015 25
Number of Products by Stage and Target, H1 2015 27
Number of Products by Stage and Mechanism of Action, H1 2015 29
Number of Products by Stage and Route of Administration, H1 2015 31
Number of Products by Stage and Molecule Type, H1 2015 33
Polycythemia Vera Therapeutics - Recent Pipeline Updates, H1 2015 56
Polycythemia Vera - Dormant Projects, H1 2015 74
Polycythemia Vera - Discontinued Products, H1 2015 75